Korro Bio initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Korro Bio with a Buy rating and $100 price target. Korro is a biotech company developing genetic medicines, specifically focused on the editing of ribonucleic acid to treat a variety of diseases, the analyst tells investors in a research note. The firm thinks Korro’s RNA editing platform is promising, since it can directly modify protein production, avoid integrations into the genome; and is reversible, enabling dose modifications or cessation of therapy, if needed.